When you think of Florida, what else crosses your mind first? Orange juice? Heat and humidity? Beaches? Disney? I don’t know if this says more about me or the state, but these days I think of stem cells. Florida and California are the two biggest hotbeds of the for-profit stem cell clinic world, each with […]
Sentinel Takes Investigational Deep Dive into Florida Stem Cell Clinic Soup Read More »
According to The Bismarck Tribune and the AP/US News & World Report, the North Dakota Attorney General’s office is investigating a stem cell clinic in that state amid complaints. From the news articles: “The clinic has been offering stem cell injections for about a week and a half. Consumer Protection Division Director Parrell Grossman says there are
‘Very Alarmed’: North Dakota AG Investigating Stem Cell Clinic Read More »
For-profit stem cell clinic secrets are bad news for patients. Stem cell clinics are in the business of making profits above all else and to make steady money they need a strong flow of patients as their paying customers for their non-FDA approved offerings. In order to keep the money pouring in, some of the
Shh! 10 stem cell clinic secrets kept from patients Read More »
On one level a reasonable argument can be made for letting terminally ill patients have a right to try experimental as yet unproven therapies, but in the real world Right-To-Try laws have many downsides. On the whole, they are likely to be negative for patients as a group. Raising the stakes is a push for
Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics? Read More »
It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a
Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »
Should patients have the Right To Try experimental therapies that could be unsafe and ineffective? What if those patients have a terminal illness and no reasonable prospects of being helpful to conventional medicine? Doesn’t it make perfect sense to let them try a risky approach if they want to do so? On the other hand,
Upcoming Right-To-Try debate: NYU’s Roxland and Goldwater’s Sandefur Read More »
Over the years I’ve been keeping my eyes open for advertising by stem cell clinics and lately the trend is big splashy ads in mainstream media including large daily newspapers such as the SacBee, the San Francisco Chronicle, and now the Seattle times (see below from today’s). These kinds of big ad buys on front or
Money talks: stem cell clinic ads mushrooming in mainstream media Read More »
ISSCR meeting review By Agnes Soos Amid the hustle and bustle of downtown Boston, nearly four thousand researchers and exhibitors gathered for the 15th Annual ISSCR Meeting. With presentations from over thirty plenary lectures, and dozens of others featured in concurrent sessions and the daily Innovation Showcases, there definitely was no shortage of exciting research
Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective Read More »
By Cátia Bandeiras, PhD Student at University of Lisbon, Portugal and Massachusetts Institute of Technology. See tweets from the conference using #ISSCR2017 @apulgarita I just wrapped up my stay at the Annual Meeting of ISSCR 2017, which happened in Boston. I decided to take advantage of the fact that I am living in Boston at
Hunting for computational approaches for stem cells at ISSCR2017 Read More »
Today’s post is the last of a three-part series on the Burt stem cell trials at Northwestern. This piece is focused on funding and the future of the trial, and also includes perspectives from patients. You can read Part 1 here and Part 2 here, which focused on issues related to potential encouragement of patient fundraising that unintentionally releases
Burt Northwestern Stem Cell MS Trial Part 3: Funding, Patient Perspectives, & the Future Read More »